Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma

American Journal of Respiratory and Critical Care Medicine

Volumn 160, Issue 1, 1999, Pages 157-161

  Derom, Eric ^a   Van Schoor, Jan ^b   Verhaeghe, Wim ^b   Vincken, Walter ^b   Pauwels, Romain ^b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; FLUTICASONE PROPIONATE; PLACEBO; TERBUTALINE;

ADRENAL SUPPRESSION; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROSSOVER PROCEDURE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; LEUKOCYTE DIFFERENTIAL COUNT; MALE; POWDER INHALER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY; TREATMENT OUTCOME;

EID: 0032794534     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.160.1.9805106     Document Type: Article

References (35)

1. NHLBI/WHO. 1996. Global initiative for asthma: global strategy for asthma management and prevention. NHLBI/WHO Workshop report. National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD. Publication No. 95-3659.
2. Toogood, J. H., J. Baskerville, B. Jennings, N. M. Lefcoe, and S. A. Johansson. 1989. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J. Allergy Clin. Immunol. 84:688-700.
3. Kamada, A. K., S. J. Szefler, R. J. Martin, H.A. Boushey, V. M. Chinchilli, J. M. Drazen, J. E. Fish, E. Israel, S. C. Lazarus, and R. F. Lemanske. 1996. Issues in the use of inhaled glucocorticoids. Am. Rev. Respir. Crit. Care Med. 153:1739-1748.
4. Capewell, S., S. Reynolds, D. Shuttleworth, C. Edwards, and A. Y. Finlay. 1990. Purpura and dermal thinning associated with high dose inhaled corticosteroids. Br. Med. J. 300:1548-1551.
5. Cumming, R. G., P. Mitchell, and S. R. Leeder. 1997. Use of inhaled corticosteroids and the risk of cataracts. N. Engl. J. Med. 337:8-14.
6. Garbe, E., J. LeLorier, J. F. Boivin, and S. Suissa. 1997. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. J.A.M.A. 227:722-727.
7. Weitzman, E. D., D. Fukushima, C. Nogeire, H. Roffwarg, T. F. Gallagher, and L. Hellman. 1971. Twenty-four hour pattern of the episodic secretion of cortisol in normal subjects. J. Clin. Endocrinol. 33: 14-22.
8. Grove, A., C. Allam, L. C. McFarlane, G. McPhate, C. M. Jackson, and B. J. Lipworth. 1994. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects. Br. J. Clin. Pharmacol. 38:527-532.
9. Boorsma, M., N. Andersson, P. Larsson, and A. Ullman. 1996. Assessment of the relative systemic potency of inhaled fluticasone and budesonide. Eur. Respir. J. 9:1427-1432.
10. Holt, P. R., D. W. Lowndes, E. Smithies, and G. T. Dixon. 1990. The effect of an inhaled steroid on the hypothalamic-pituitary-adrenal axis-which test should be used? Clin. Exp. Allergy 20:145-149.
11. Nicolaizik, W. H., J. L. Marchant, M. A. Preece, and J. O. Warner. 1994. Endocrine and lung function in asthmatic children on inhaled corticosteroids. Am. J. Respir. Crit. Care Med. 150:624-628.
12. Grahnén, A., S. Å. Eckernås, R. M. Brundin, and A. Ling-Andersson. 1994. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers. Br. J. Clin. Pharmacol. 38:521-525.
13. Lönnebo, A., A. Grahnén, B. Jansson, R. M. Brundin, A. Ling-Andersson, and S. Å. Eckernås. 1996. An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers. Eur. J. Clin. Pharmacol. 49:459-463.
14. Donnelley, R., K. M. Williams, A. B. Baker, C.-A. Badcock, R. O. Day, and J. P. Seale. 1997. Effects of budesonide and fluticasone on 24-hour plasma cortisol: a dose-response study. Am. J. Respir. Crit. Care Med. 156:1746-1751.
15. American Thoracic Society. 1987. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am. Rev. Respir. Dis. 136:225-244.
16. Quanjer, P. H., G. J. Tammeling, J. E. Cotes, O. F. Pedersen, P. Peslin, and J. C. Yernault. 1993. Lung volume and forced ventilatory flows. Eur. Respir. J. 6(Suppl. 16):5-40.
17. Ayres, J. G., E. D. Bateman, B. Lundbäck, and T. A. J. Harris. 1995. High dose fluticasone propionate, 1 μg daily, versus fluticasone propionate, 2 μg daily, or budesonide, 1.6 μg daily, in patients with chronic severe asthma. Eur. Respir. J. 8:579-586.
18. Boc, J., P. Bakke, T. Rødølen, E. Skovlund, and A. Gulsvik. 1994. High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Eur. Respir. J. 7:2179-2184.
19. Ebden, P., A. Jenkins, G. Houston, and B. H. Davies. 1986. Comparison of two high dose corticosteroid aerosol treatments, beclomethasone dipropionate (1500 μg/day) and budesonide (1600 μg/day), for chronic asthma. Thorax 41:869-874.
20. Greening, A. P. 1994. Clinical trials of high-dose fluticasone propionate. Respir. Med. 88(Suppl. A):17-23.
21. Nikolaizik, W. H., M. A. Preece, and J. O. Warner. 1997. One year follow-up study of endocrine and lung function of asthmatic children on inhaled budesonide. Eur. Respir. J. 10:2596-2601.
22. Clark, D. J., A. Grove, R. I. Cargill, and B. J. Lipworth. 1996. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262-266.
23. Clark, D. J., and B. J. Lipworth. 1997. Adrenal suppression with chronic dosing of fluticasone propionate compared with budesonide in adult asthmatic patients. Thorax 52:55-58.
24. Harding, S. M. 1990. The human pharmacology of fluticasone propionate. Respir. Med. 84(Suppl. A):25-29.
25. Ryrfeldt, Ä., P. Andersson, S. Edsbäcker, M. Tönnesson, D. Davies, and R. Pauwels. 1982. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur. J. Respir. Dis. 63:86-95.
26. Lipworth, B. J. 1995. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 50:105-110.
27. Olsson, B., and L. Borgström. 1996. Author's response. J. Aerosol Med. 9:281-283.
28. Thorsson, L., S. Edsbäcker, and T. B. Conradson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler P-MDI. Eur. Respir. J. 7:1839-1844.
29. Högger, P., and P. Rohdewald. 1994. Binding kinetics of fluticasone propionate to the human glucocorticoid receptor. Steroids 59:597-602.
30. Mackie, A. E., G. P. Ventresca, J. A. Moss, and A. Bye. 1995. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 40:198P.
31. Thorsson, L., K. Dahlström, S. Edsbäcker, A. Källén, J. Paulson, and J.-E. Wirén. 1997. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br. J. Clin. Pharmacol. 43:155-161.
32. Hochhaus, G., H. Möllmann, H. Derendorf, and R. J. Gonzalez-Rothi. 1997. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J. Clin. Pharmacol. 37:881-892.
33. Evans, P. M., B. J. O'Connor, R. W. Fuller, P. J. Barnes, and K. F. Chung. 1993. Effect of inhaled corticosteroids on peripheral blood eosinophil counts and density profiles in asthma. J. Allergy Clin. Immunol. 91:643-650.
34. 2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma: a randomized, double-blind, parallel-group controlled trial. J. Allergy Clin. Immunol. 90:32-42.
35. Ädelroth, E., L. Rosenhall, S. Å. Johansson, M. Linden, and P. Venge. 1990. Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage. Am. Rev. Respir. Dis. 142:91-99.